Adjuvant Trastuzumab in HER2-Positive Breast Cancer

Dennis J. Slamon, W. Eiermann, Nicholas J. Robert, Tadeusz Pieńkowski, Miguel Martín, Michael F. Press, John R. Mackey, John A. Glaspy, Arlene Chan, Marek Pawlicki, Tamás Pintér, Vicente Valero, Mei-Ching Liu, Guido Sauter, Gϋnter von Minckwitz, F. Visco, Valerie Bée, Marc Buyse, Belguendouz Bendahmane, Isabelle Tabah-Fisch, Mary-Ann Lindsay, A. Riva, John Crown

New England Journal of Medicine, 2011

University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Krankenhaus vom Roten Kreuz, Olgahospital, The Maria Sklodowska-Curie National Research Institute of Oncology, Hospital Clínico San Carlos, University of Southern California, City Clinical Oncology Center, University of Alberta, Mount Medical Centre, The University of Texas MD Anderson Cancer Center, Koo Foundation Sun Yat-Sen Cancer Center, Universität Hamburg, University Medical Center Hamburg-Eppendorf, Klinik für Frauenheilkunde, Breast Cancer Alliance, International Breast Cancer Study Group, International Drug Development Institute (Belgium), Sanofi (Mexico), Cancer Trials Ireland, St. Vincent's University Hospital

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

2756

Citations

View on Google Scholar

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

Abstract

Journal Details

Join JournalsHub

Welcome Back